We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alternate Day Buprenorphine Administration, Phase IX - 14

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000232
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : May 6, 2016
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont

Brief Summary:
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 0 participants
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Alternate Day Buprenorphine Administration, Phase IX
Study Start Date : March 1992

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Drug use
  2. Opioid withdrawal
  3. Opioid agonist effects
  4. Dose identification
  5. Pupil diameter


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 51 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000232


Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont

ClinicalTrials.gov Identifier: NCT00000232     History of Changes
Other Study ID Numbers: NIDA-06969-14
R01DA006969 ( U.S. NIH Grant/Contract )
R01-06969-14
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: May 6, 2016
Last Verified: April 1994

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists